Head-to-head evidence
AZD1705 vs Solbinsiran
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Atherosclerotic Cardiovascular Disease
Shared mechanism: ANGPTL3 · full Atherosclerotic Cardiovascular Disease pipeline
AZD1705
Developed by AstraZeneca
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Solbinsiran
Developed by Eli Lilly
NCT05256654 · Phase 2 · completed
The study randomized 205 participants to three solbinsiran doses or placebo and masked both participants and investigators. Its primary endpoint was a laboratory biomarker rather than a hard clinical outcome, and the ApoB comparison was mixed across doses: significant for 400 mg but not for 100 mg or 800 mg, supporting moderate evidence rather than the highest grade.
Next expected readout: March 2027 · NCT07269210 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: AZD1705's landscape · Solbinsiran's landscape